Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
Cork, Ireland (ots/PRNewswire) - Janssen R&D Ireland (Janssen) announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) ...
mehr